RVMD stock forecast, quote, news & analysis
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers... Show more
Why Revolution Medicines (RVMD) Is Up +41% in the Last 30 Days
Key Takeaways
- Revolution Medicines (RVMD) stock surged +41% over the past 30 days, primarily driven by positive topline results from a pancreatic cancer trial announced mid-period.
- The stock experienced high volatility with a sharp spike followed by consolidation, reflecting investor enthusiasm for clinical progress.
- Over the past quarter, shares rose +44%, fueled by cumulative advancements in the company's RAS inhibitor pipeline.
- Analyst upgrades and raised price targets post-trial data boosted market sentiment.
- Upcoming first-quarter earnings on May 6 could provide further insights into pipeline development.
- Biotech sector trends in precision oncology supported the upward momentum.
Revolution Medicines (RVMD) Company Overview and Market Position
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. RAS refers to a family of genes frequently mutated in difficult-to-treat cancers like pancreatic, lung, and colorectal. The company's core business model revolves around its proprietary platform for RAS(ON) inhibitors and RAS companion inhibitors, which aim to block mutated RAS proteins in their active state. Key pipeline candidates include daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), targeting specific RAS mutations.
In the competitive biotechnology landscape, Revolution Medicines stands out for its leadership in RAS-targeted therapies, an area with high unmet need. Its fundamentals, including advancing clinical data and partnerships, directly explain recent stock price strength, as positive trial outcomes validate the platform's potential in high-mortality cancers.
Revolution Medicines (RVMD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RVMD stock climbed +41%, moving from approximately $99 to a close of $139.48. The performance was volatile and trend-driven, featuring a dramatic 40%+ single-day surge mid-period followed by profit-taking and consolidation around $130-$150.
In the past quarter, shares advanced +44% from around $97. The trajectory showed early gains, a mid-quarter pullback, and a strong recovery, characterized by news-driven spikes amid broader biotech market trends. Overall, the stock trended upward with elevated volume on key catalysts, outperforming many peers in precision oncology.
What Drove RVMD Stock Price in the Last 30 Days
The primary catalyst for RVMD's +41% gain was positive topline results from a pancreatic ductal adenocarcinoma (PDAC) trial on April 13, sparking a 33%-plus intraday surge from $96 to over $136. The data highlighted efficacy of the company's RAS inhibitors in this aggressive cancer, fueling optimism about near-term milestones.
Analyst reactions amplified the move: Leerink, Oppenheimer, and H.C. Wainwright raised price targets to $165, $169, and higher, citing strong trial potential. A subsequent $1 billion dual stock and warrant offering was announced, providing capital for pipeline advancement without immediate dilution concerns derailing momentum.
Additional Phase 1 data for a lung cancer drug further supported sentiment. Sector influences, including competitor setbacks like Erasca's (ERAS) trial issues, highlighted RVMD's relative strength. High trading volume confirmed conviction buying on these developments.
What Drove RVMD Stock Performance Over the Last Quarter
The quarter's +44% rise built on sustained clinical momentum. Early January updates on PDAC positioning from Stifel and other firms triggered a run-up to $123, establishing upward bias despite a late-January dip to $97 on profit-taking.
Macro biotech trends favored oncology innovators amid demand for targeted therapies. Institutional interest grew, evidenced by billionaire investor positioning, while insider sales were routine and did not deter gains. The April PDAC trial success proved the strongest cumulative force, reinforcing the RAS platform's viability and overshadowing minor volatility from market rotations.
Competitive dynamics in RAS space bolstered RVMD's position, with its multi-mutation approach differentiating it from single-asset rivals.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze and trade thousands of tickers across various markets. These curated bots are selected based on recent performance metrics like win rate, profit factor, and Sharpe ratio, highlighting those excelling in current conditions. Strategies range from momentum and mean reversion to machine learning pattern recognition, spanning short-term day trades to longer swing positions. Users can review detailed backtests, live results, and risk profiles to select bots aligning with their portfolio. Explore the page to discover relevant AI tools for RVMD or similar biotech stocks and enhance your trading with data-backed automation.
RVMD Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings on May 6 for pipeline updates, cash position post-offering, and guidance on RAS inhibitor trials. Further data readouts from PDAC, lung cancer, and other studies will be critical catalysts.
Industry trends in precision oncology, including regulatory feedback and combination therapy progress, could influence sentiment. Macro factors like interest rates and biotech funding environment remain relevant. Strategic developments such as partnerships or expanded trials, alongside clinical risks like trial delays or safety issues, warrant attention. Analyst revisions and institutional flows will signal shifting views.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for RVMD turns positive, indicating new upward trend
RVMD saw its Momentum Indicator move above the 0 level on June 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RVMD just turned positive on June 18, 2026. Looking at past instances where RVMD's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 252 cases where RVMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RVMD broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RVMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.474) is normal, around the industry mean (20.978). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). RVMD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (366.957).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology company, which focused on developing novel targeted therapies and engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment.
Industry Biotechnology